Investors Purchase Large Volume of Put Options on Corcept Therapeutics (NASDAQ:CORT)

Corcept Therapeutics Incorporated (NASDAQ:CORT) saw unusually large options trading on Friday. Stock investors purchased 4,870 put options on the stock. This is an increase of approximately 78% compared to the typical daily volume of 2,737 put options.

Analysts Set New Price Targets

A number of equities analysts have recently commented on CORT shares. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Corcept Therapeutics in a report on Monday, December 29th. Truist Financial set a $50.00 price objective on shares of Corcept Therapeutics in a research note on Wednesday, December 31st. UBS Group started coverage on shares of Corcept Therapeutics in a research note on Tuesday, December 16th. They set a “neutral” rating and a $95.00 target price for the company. Wolfe Research cut Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $30.00 price target on the stock. in a research report on Wednesday, December 31st. Finally, Wall Street Zen downgraded Corcept Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, October 18th. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $83.50.

Insider Transactions at Corcept Therapeutics

In other news, insider Sean Maduck sold 20,000 shares of the business’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $79.52, for a total value of $1,590,400.00. Following the completion of the sale, the insider directly owned 7,904 shares of the company’s stock, valued at approximately $628,526.08. The trade was a 71.67% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Joseph Douglas Lyon sold 5,000 shares of the company’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $79.53, for a total value of $397,650.00. Following the completion of the sale, the insider directly owned 10,277 shares of the company’s stock, valued at approximately $817,329.81. This trade represents a 32.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 194,500 shares of company stock worth $14,186,410 over the last three months. 20.80% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Corcept Therapeutics

Several institutional investors have recently modified their holdings of CORT. Advisory Services Network LLC acquired a new position in Corcept Therapeutics during the third quarter worth $25,000. Clearstead Advisors LLC boosted its position in shares of Corcept Therapeutics by 163.6% in the 3rd quarter. Clearstead Advisors LLC now owns 311 shares of the biotechnology company’s stock worth $26,000 after buying an additional 193 shares in the last quarter. Golden State Wealth Management LLC acquired a new stake in Corcept Therapeutics in the 2nd quarter valued at about $28,000. Huntington National Bank increased its holdings in Corcept Therapeutics by 54.0% during the 2nd quarter. Huntington National Bank now owns 479 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 168 shares in the last quarter. Finally, Hantz Financial Services Inc. increased its holdings in Corcept Therapeutics by 598.5% during the 3rd quarter. Hantz Financial Services Inc. now owns 461 shares of the biotechnology company’s stock valued at $38,000 after acquiring an additional 395 shares in the last quarter. Hedge funds and other institutional investors own 93.61% of the company’s stock.

Corcept Therapeutics Trading Up 6.5%

NASDAQ:CORT opened at $43.98 on Friday. Corcept Therapeutics has a 1 year low of $32.99 and a 1 year high of $117.33. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.07 and a current ratio of 3.14. The stock has a fifty day moving average price of $65.24 and a two-hundred day moving average price of $71.10. The stock has a market capitalization of $4.63 billion, a price-to-earnings ratio of 49.98 and a beta of 0.23.

Corcept Therapeutics (NASDAQ:CORT) last issued its earnings results on Tuesday, November 4th. The biotechnology company reported $0.16 EPS for the quarter, missing the consensus estimate of $0.18 by ($0.02). The company had revenue of $207.64 million for the quarter, compared to analysts’ expectations of $223.78 million. Corcept Therapeutics had a return on equity of 15.99% and a net margin of 14.19%.Corcept Therapeutics’s revenue for the quarter was up 13.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.41 earnings per share. As a group, sell-side analysts anticipate that Corcept Therapeutics will post 1.36 earnings per share for the current fiscal year.

Corcept Therapeutics News Roundup

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Phase 3 ROSELLA met its overall survival primary endpoint in platinum‑resistant ovarian cancer — a clear clinical success that materially improves relacorilant’s value thesis and is the main driver of the move. Overall Survival Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
• Positive Sentiment: Multiple trade and analyst outlets reported the OS win, reinforcing market confidence that the drug could drive future revenue and partnership interest. CORT Rises as Relacorilant Meets OS Endpoint in Ovarian Cancer Study
• Positive Sentiment: Wall‑street coverage (e.g., Reuters) flagged the late‑stage success, increasing visibility with institutional investors and media, which can amplify buying interest. Corcept’s cancer drug meets main goal in late-stage trial
• Positive Sentiment: Analyst optimism picked up: Canaccord raised its price target to $100 and maintained a buy rating, signaling upside potential versus the current price and likely supporting additional demand. CORT Corcept Therapeutics price target raised by Canaccord
• Neutral Sentiment: Options flow shows elevated activity: about 4,870 put contracts were purchased (≈78% above the typical daily put volume), indicating some investors are hedging or speculating on near‑term volatility rather than a clear directional consensus. (No external link)
• Negative Sentiment: Regulatory and legal overhangs remain — shareholder law firms (Hagens Berman and Pomerantz) launched investigations tied to the company’s prior FDA complete response letter for relacorilant in Cushing’s syndrome and the sharp December sell‑off, which could lead to litigation costs or disclosure risk. CORT INVESTIGATION ALERT: Investigation Launched into Corcept Therapeutics (CORT), Hagens Berman Encourages Investors to Contact Firm
• Negative Sentiment: Remember the December FDA complete response letter for relacorilant (Cushing’s syndrome) that previously drove a large share price drop — regulatory uncertainty remains a material risk even after the oncology win. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated – CORT

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.